Novavax has delivered a sharp mix of gains and losses over the years, and the recent rebound puts fresh attention on a basic ...

Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that ...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at ...

Novavax jumped on plague fears, but weak finances and no clear drug path remain. Click here to read this latest analysis of ...

Novavax Inc. NVAX shares are pulling back Tuesday after a more than 20% surge Monday. Vaccine stocks rallied after a ...

Novavax (NVAX) stock surged 16% after Sanofi’s combination vaccine trial cleared key European approvals, triggering a ...

Wall Street healthcare weekly recap: top S&P 500 movers plus key news on Moderna, BD manufacturing, CSL-Alentis deal and Viatris-Pacira.

A suspected plague death at a Siberian research institute has investors reaching for the pandemic playbook again. One of ...

Novavax, Moderna and other vaccine stocks rallied after a lab worker in Russia died following suspected plague exposure, WHO ...

A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) announced better-than-expected revenue in Q2 CY2026, but sales fell by 76 ...